{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:43Z","timestamp":1787962303123,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Biologicals, such as anti-tumor necrosis factor (anti-TNF), reduce cardiovascular disease (CVD) in patients with inflammatory rheumatic diseases. Impaired renal function is a known predictor of CVD and elevated in ankylosing spondylitis (AS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To assess the effect of anti-TNF on renal function in patients with AS and whether anti-TNF use is safe in AS patients with pre-existing risk factors for renal decline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Biological-na\u00efve consecutive AS patients treated with etanercept or adalimumab were prospectively followed from 2005 to 2014. Renal function was determined by calculation of the estimated glomerular filtration rate (eGFR), estimated with the abbreviated modification of diet in renal disease (MDRD) formula. The effect of anti-TNF on eGFR was analyzed using mixed model analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>211 AS patients were followed for a median of 156 (36\u2013286) weeks. Overall mixed model analyses showed a significant decrease of eGFR over time (<jats:italic>\u03b2<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.040, <jats:italic>p<\/jats:italic>\u2009=\u20090.000), although this association did not remain significant after adjustment for responding to anti-TNF, alcohol use, disease duration, body mass index (BMI), C-reactive protein (CRP), and disease activity (<jats:italic>\u03b2<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.018, <jats:italic>p<\/jats:italic>\u2009=\u20090.094). However, patients with pre-existing risk factors for renal decline did have a significant change in eGFR over time (<jats:italic>\u03b2<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.029, <jats:italic>p<\/jats:italic>\u2009=\u20090.006).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We found a significant change in eGFR over time, although this small decrease was not clinically relevant. This study further demonstrates that anti-TNF does not affect renal function in AS patients with and without existing risk factors for renal decline, which means that use of anti-TNF is safe concerning renal function in patients with AS.<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Previous studies showed that biologicals, such as anti-tumor necrosis factor (anti-TNF), reduce cardiovascular disease (CVD) in patients with inflammatory rheumatic diseases, such as ankylosing spondylitis (AS).<\/jats:italic><jats:italic>\u2022 Impaired renal function is a known predictor of CVD, and also a known concern for many AS patients.<\/jats:italic><jats:italic>\u2022 Use of anti-TNF is safe with regard to renal function in patients with AS.<\/jats:italic><jats:italic>\u2022 The effect of anti-TNF on CVD in AS patients does not seem to be mediated by changes in renal function.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-022-06330-9","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T21:03:02Z","timestamp":1660338182000},"page":"3747-3752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study"],"prefix":"10.1007","volume":"41","author":[{"given":"I. A. P.","family":"Swart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Visman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Heslinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. E.","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"van Denderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"6330_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","volume":"345","author":"JD Reveille","year":"2013","unstructured":"Reveille JD, Weisman MH (2013) The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci 345:431\u2013436","journal-title":"Am J Med Sci"},{"key":"6330_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ (2014) Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 53:650\u2013657","journal-title":"Rheumatology (Oxford)"},{"key":"6330_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/annrheumdis-2016-209315","volume":"76","author":"JK Eriksson","year":"2017","unstructured":"Eriksson JK, Jacobsson L, Bengtsson K, Askling J (2017) Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis 76:364\u2013370","journal-title":"Ann Rheum Dis"},{"key":"6330_CR4","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1056\/NEJMoa041747","volume":"351","author":"L Smeeth","year":"2004","unstructured":"Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351:2611\u20132618","journal-title":"N Engl J Med"},{"key":"6330_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74:480\u2013489","journal-title":"Ann Rheum Dis"},{"key":"6330_CR6","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00296-012-2624-9","volume":"33","author":"SH Lee","year":"2013","unstructured":"Lee SH, Lee EJ, Chung SW, Song R, Moon JY, Lee SH et al (2013) Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int 33:1689\u20131692","journal-title":"Rheumatol Int"},{"key":"6330_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/BF01451293","volume":"17","author":"ES Strobel","year":"1998","unstructured":"Strobel ES, Fritschka E (1998) Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 17:524\u2013530","journal-title":"Clin Rheumatol"},{"key":"6330_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/acr.22176","volume":"66","author":"AR Levy","year":"2014","unstructured":"Levy AR, Szabo SM, Rao SR, Cifaldi M, Maksymowych WP (2014) Estimating the occurrence of renal complications among persons with ankylosing spondylitis. Arthritis Care Res (Hoboken) 66:440\u2013445","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6330_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.amjmed.2006.02.015","volume":"120","author":"K Gooch","year":"2007","unstructured":"Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M et al (2007) NSAID use and progression of chronic kidney disease. Am J Med 120:280\u2013287","journal-title":"Am J Med"},{"key":"6330_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00296-014-3146-4","volume":"35","author":"HW Kim","year":"2015","unstructured":"Kim HW, Lee CK, Cha HS, Choe JY, Park EJ, Kim J (2015) Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Rheumatol Int 35:727\u2013734","journal-title":"Rheumatol Int"},{"key":"6330_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/acr.21800","volume":"65","author":"K Sumida","year":"2013","unstructured":"Sumida K, Ubara Y, Suwabe T, Hayami N, Hiramatsu R, Hasegawa E et al (2013) Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. Arthritis Care Res (Hoboken) 65:471\u2013475","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6330_CR12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00296-009-1108-z","volume":"30","author":"SK Cho","year":"2010","unstructured":"Cho SK, Sung YK, Park S, Bae SC (2010) Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis. Rheumatol Int 30:1519\u20131522","journal-title":"Rheumatol Int"},{"key":"6330_CR13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00296-012-2646-3","volume":"33","author":"S Donmez","year":"2013","unstructured":"Donmez S, Pamuk ON, Pamuk GE, Aydogdu E, Inman R (2013) Secondary amyloidosis in ankylosing spondylitis. Rheumatol Int 33:1725\u20131729","journal-title":"Rheumatol Int"},{"key":"6330_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382:339\u2013352","journal-title":"Lancet"},{"key":"6330_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"6330_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/ard.2005.040758","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65:316\u2013320","journal-title":"Ann Rheum Dis"},{"key":"6330_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"139","author":"AS Levey","year":"2003","unstructured":"Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137\u2013147","journal-title":"Ann Intern Med"},{"key":"6330_CR18","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landew\u00e9 R, Rudwaleit M, Braun J; Assessment of Spondylo Arthritis International Society (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6):905\u2013908","DOI":"10.1136\/ard.2011.151563"},{"issue":"8","key":"6330_CR19","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/jech-2014-204962","volume":"69","author":"X Qin","year":"2015","unstructured":"Qin X, Wang Y, Li Y, Xie D, Tang G, Wang B, Wang X, Xu X, Xu X, Hou F (2015 Aug) Risk factors for renal function decline in adults with normal kidney function: a 7-year cohort study. J Epidemiol Community Health 69(8):782\u2013788","journal-title":"J Epidemiol Community Health"},{"key":"6330_CR20","doi-asserted-by":"crossref","unstructured":"Chakraborty H, Gu H (2009) A mixed model approach for intent-to-treat analysis in longitudinal clinical trials with missing values [Internet]. RTI Press, Research Triangle Park (NC)","DOI":"10.3768\/rtipress.2009.mr.0009.0903"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06330-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06330-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06330-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T13:09:46Z","timestamp":1668172186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06330-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6330"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06330-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"31 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in compliance with the declaration of Helsinki and approved by the local Medical Ethics Committee of Slotervaart Hospital and Reade. All patients gave written informed consent prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}